Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Risk/Benefit Of Asthma Drugs To Be Debated At Future Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA awaits data from controlled trials of seven long-acting beta agonists before bringing them back for panel review later this year.

You may also be interested in...



AstraZeneca Submits Symbicort For Asthmatics As Young As Six

Lead investigator touts inhaler's safety profile.

AstraZeneca Submits Symbicort For Asthmatics As Young As Six

Lead investigator touts inhaler's safety profile.

AstraZeneca Wants COPD Label For Symbicort

Newly reported trials prove safety and efficacy, company says.

Related Content

Topics

UsernamePublicRestriction

Register

PS067529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel